Shares of Balchem Co. (NASDAQ:BCPC) have received an average recommendation of “Hold” from the six analysts that are currently covering the company, Marketbeat reports. One analyst has rated the stock with a sell rating, two have issued a hold rating and three have assigned a buy rating to the company. The average 1-year price objective among analysts that have updated their coverage on the stock in the last year is $122.33.
Several analysts have weighed in on the stock. BidaskClub cut shares of Balchem from a “sell” rating to a “strong sell” rating in a research note on Wednesday, November 28th. Pivotal Research raised shares of Balchem from a “hold” rating to a “buy” rating and upped their price objective for the stock from $95.00 to $100.00 in a research note on Tuesday, November 6th. ValuEngine cut shares of Balchem from a “buy” rating to a “hold” rating in a research note on Thursday, November 1st. Sidoti raised shares of Balchem from a “neutral” rating to a “buy” rating and set a $127.00 price objective on the stock in a research note on Tuesday, October 16th. Finally, HC Wainwright set a $140.00 price objective on shares of Balchem and gave the stock a “buy” rating in a research note on Monday, October 15th.
In related news, Director Daniel E. Knutson purchased 650 shares of the firm’s stock in a transaction dated Tuesday, November 13th. The shares were acquired at an average cost of $89.11 per share, with a total value of $57,921.50. Following the completion of the purchase, the director now directly owns 1,495 shares of the company’s stock, valued at $133,219.45. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. 1.02% of the stock is owned by corporate insiders.
Institutional investors and hedge funds have recently added to or reduced their stakes in the company. Hsbc Holdings PLC bought a new stake in shares of Balchem during the third quarter valued at approximately $212,000. Cubist Systematic Strategies LLC bought a new stake in shares of Balchem during the second quarter valued at approximately $218,000. Granahan Investment Management Inc. MA bought a new stake in shares of Balchem during the second quarter valued at approximately $224,000. Bbva Compass Bancshares Inc. bought a new stake in shares of Balchem during the third quarter valued at approximately $226,000. Finally, Sigma Planning Corp bought a new stake in shares of Balchem during the second quarter valued at approximately $229,000. 88.17% of the stock is currently owned by institutional investors and hedge funds.
Shares of NASDAQ:BCPC opened at $81.01 on Wednesday. The firm has a market capitalization of $2.64 billion, a P/E ratio of 27.91 and a beta of 0.94. Balchem has a 1 year low of $70.23 and a 1 year high of $117.79. The company has a debt-to-equity ratio of 0.27, a current ratio of 3.42 and a quick ratio of 2.33.
Balchem (NASDAQ:BCPC) last released its earnings results on Tuesday, November 6th. The basic materials company reported $0.73 earnings per share for the quarter, topping the Zacks’ consensus estimate of $0.61 by $0.12. The firm had revenue of $155.04 million during the quarter, compared to analyst estimates of $163.66 million. Balchem had a net margin of 15.67% and a return on equity of 14.51%. The business’s revenue was up 2.9% on a year-over-year basis. During the same quarter in the previous year, the business earned $0.63 EPS. As a group, equities analysts anticipate that Balchem will post 2.45 EPS for the current year.
Balchem Corporation develops, manufactures, and markets specialty performance ingredients and products for the food, nutritional, feed, pharmaceutical, medical sterilization, and industrial markets in the United States and internationally. The company's Human Nutrition & Health segment supplies ingredients in the food and beverage industry.
Featured Article: Short Selling – Explanation For Shorting Stocks
Receive News & Ratings for Balchem Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Balchem and related companies with MarketBeat.com's FREE daily email newsletter.